The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Nitro-Group-Containing Drugs
Open accessAbstract
The nitro group is considered to be a versatile and unique functional group in medicinal chemistry. Despite a long history of use in therapeutics, the nitro group has toxicity issues and is often categorized as a structural alert or a toxicophore, and evidence related to drugs containing nitro groups is rather contradictory. In general, drugs containing nitro groups have been extensively associated with mutagenicity and genotoxicity. In this context, efforts toward the structure-mutagenicity or structure-genotoxicity relationships have been undertaken. The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues. In addition, recent advances in the field of anticancer, antitubercular and antiparasitic agents containing nitro groups, along with a patent survey on hypoxia-activated prodrugs containing nitro groups, are also covered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Nitroaromatic Compounds, from Synthesis to Biodegradation
Ju, K.-S., & Parales, R. E. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00006-10 · Cited by 931
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Mutagenicity of Nitroaromatic Compounds
Purohit, V., & Basu, A. K. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000002x · Cited by 450
The mechanism of action of PA-824: Novel insights from transcriptional profiling
Manjunatha, U., Boshoff, H. I. M., & Barry, C. E. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.3.7926 · Cited by 319
The tumor microenvironment and metastatic disease
Lunt, S. J., Chaudary, N., & Hill, R. P. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9182-2 · Cited by 298
Significance of nitroimidazole compounds and hypoxia‐inducible factor‐1 for imaging tumor hypoxia
Kizaka‐Kondoh, S., & Konse‐Nagasawa, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01195.x · Cited by 255
Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
Duan, J.-X., Jiao, H., Kaizerman, J., Stanton, T., Evans, J. W., Lan, L., Lorente, G., Banica, M., Jung, D., Wang, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701028q · Cited by 239
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238
Trefzer, C., Rengifo-Gonzalez, M., Hinner, M. J., Schneider, P., Makarov, V., Cole, S. T., & Johnsson, K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106357w · Cited by 215
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases
Ang, C. W., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00143 · Cited by 195
Bioactivation and Hepatotoxicity of Nitroaromatic Drugs
Boelsterli, U., Ho, H., Zhou, S., & Yeow Leow, K. (2006) · Current Drug Metabolism · doi:10.2174/138920006778520606 · Cited by 186
Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3237 · Cited by 185
Brooks, D. J. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.8.1071 · Cited by 182
Benigni, R. (2005) · Chemical Reviews · doi:10.1021/cr030049y · Cited by 172
Tinidazole: A nitroimidazole antiprotozoal agent
Fung, H. B., & Doan, T.-L. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.12.012 · Cited by 161
Biologic Activity of Hydroxylamine: A Review
Gross, P., & Smith, R. P. (1985) · Critical Reviews in Toxicology · doi:10.3109/10408448509023765 · Cited by 155
Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
Rogers, J. L., Bayeh, L., Scheuermann, T. H., Longgood, J. C., Key, J., Naidoo, J., Melito, L. M., Shokri, C., Frantz, D. E., Bruick, R. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301847z · Cited by 150
Wardman, P. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372959 · Cited by 150
Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Wilkinson, S. R., Bot, C., Kelly, J. M., & Hall, B. S. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796575894 · Cited by 133
Karabanovich, G., Zemanová, J., Smutný, T., Székely, R., Šarkan, M., Centárová, I., Vocat, A., Pávková, I., Čonka, P., Němeček, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00608 · Cited by 127
Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
Gulley, J. L., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2656 · Cited by 118
Alirol, E., Schrumpf, D., Heradi, J. A., Riedel, A., de Patoul, C., Quere, M., & Chappuis, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis886 · Cited by 114
Thompson, A. M., Sutherland, H. S., Palmer, B. D., Kmentová, I., Blaser, A., Franzblau, S. G., Wan, B., Wang, Y., Ma, Z., & Denny, W. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200377r · Cited by 112
Cho, Y., Ioerger, T. R., & Sacchettini, J. C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800328v · Cited by 109
Palmer, B. D., Thompson, A. M., Sutherland, H. S., Blaser, A., Kmentová, I., Franzblau, S. G., Wan, B., Wang, Y., Ma, Z., & Denny, W. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901207n · Cited by 108
Kim, P., Zhang, L., Manjunatha, U. H., Singh, R., Patel, S. J., Jiřiček, J., Keller, T. H., Boshoff, H. I., Barry, C. E., & Dowd, C. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801246z · Cited by 101
Thompson, A. M., Blaser, A., Anderson, R. F., Shinde, S. S., Franzblau, S. G., Ma, Z., Denny, W. A., & Palmer, B. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801087e · Cited by 97
Rami, M., Dubois, L. J., Parvathaneni, N.-K., Alterio, V., van Kuijk, S. J. A., Monti, S. M., Lambin, P., Simone, G. D., Supuran, C. T., & Winum, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4009532 · Cited by 93
Arend, R. C., Londoño-Joshi, A. I., Gangrade, A., Katre, A. A., Kurpad, C., Li, Y., Samant, R. S., Li, P., Landen, C. N., Yang, E. S.-H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13466 · Cited by 93
Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents
Tangallapally, R. P., Yendapally, R., Lee, R. E., Hevener, K. E., Jones, V., Lenaerts, A. J. M., McNeil, M., Wang, Y., Franzblau, S. G., & Lee, R. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049972y · Cited by 90
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
Patterson, S., Wyllie, S., Norval, S., Stojanovski, L., Simeons, F. R. C., Auer, J. L., Osuna‐Cabello, M., Read, K. D., & Fairlamb, A. H. (2016) · eLife · doi:10.7554/elife.09744 · Cited by 85
Shamovsky, I. L., Ripa, L., Börjesson, L., Mee, C. D., Nordén, B., Hansen, P., Hasselgren, C., O'Donovan, M. R., & Sjö, P. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206427u · Cited by 84
Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
O'Connor, L. J., Cázares-Körner, C., Saha, J., Evans, C. N. G., Stratford, M. R. L., Hammond, E. M., & Conway, S. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.034 · Cited by 82
Coe, K. J., Jia, Y., Ho, H. K., Rademacher, P. M., Bammler, T. K., Beyer, R. P., Farin, F. M., Woodke, L., Plymate, S. R., Fausto, N., et al. (2007) · Chemical Research in Toxicology · doi:10.1021/tx7001349 · Cited by 75
Nitroimidazole-refractory giardiasis: a growing problem requiring rational solutions
Carter, E. R., Nabarro, L., Hedley, L., & Chiodini, P. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.028 · Cited by 74
Cázares-Körner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O’Connor, L. J., Olcina, M. M., Christlieb, M., Conway, S. J., & Hammond, E. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4001537 · Cited by 73
Mook, R. A., Wang, J., Ren, X.-R., Chen, M., Spasojević, I., Barak, L. S., Lyerly, H. K., & Chen, W. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.001 · Cited by 68
Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue
Damen, E. W. P., Nevalainen, T., van den Bergh, T. J. M., de Groot, F. M. H., & Scheeren, H. W. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00235-8 · Cited by 64
Thompson, A. M., O’Connor, P. D., Marshall, A. J., Yardley, V., Maes, L. J. R. M., Gupta, S. K. D., Launay, D., Braillard, S., Chatelain, E., Franzblau, S. G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00034 · Cited by 63
Blaser, A., Palmer, B. D., Sutherland, H. S., Kmentová, I., Franzblau, S. G., Wan, B., Wang, Y., Ma, Z., Thompson, A. M., & Denny, W. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2012276 · Cited by 59
Kamal, Ä., Hussaini, S. M. A., Faazil, S., Poornachandra, Y., Reddy, G. N., Kumar, C. G., Rajput, V. S., Rani, C., Sharma, R., Khan, I. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.010 · Cited by 57
Grigsby, P. W., Winter, K. A., Wasserman, T. H., Marcial, V. A., Rotman, M. Z., Cooper, J. S., Keys, H. M., Asbell, S. O., & Phillips, T. L. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00054-1 · Cited by 56
Seow, H. A., Penketh, P. G., Shyam, K., Rockwell, S., & Sartorelli, A. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409013102 · Cited by 56
Novel 3-Nitrotriazole-Based Amides and Carbinols as Bifunctional Antichagasic Agents
Papadopoulou, M. V., Bloomer, W. D., Lepesheva, G. I., Rosenzweig, H. S., Kaiser, M., Aguilera‐Venegas, B., Wilkinson, S. R., Chatelain, E., & Ioset, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5015742 · Cited by 55
Trunz, B. B., Jędrysiak, R. G., Tweats, D. J., Brun, R., Kaiser, M., Suwiński, J., & Torreele, E. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.071 · Cited by 53
Tercel, M., Atwell, G. J., Yang, S., Stevenson, R. J., Botting, K. J., Boyd, M., Smith, E., Anderson, R. F., Denny, W. A., Wilson, W. R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901202b · Cited by 52
Ikeda, Y., Hisano, H., Nishikawa, Y., & Nagasaki, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00011 · Cited by 52
Rodríguez, J., Gerpe, A., Aguirre, G., Kemmerling, U., Piro, O. E., Arán, V. J., Maya, J. D., Olea‐Azar, C., González, M., & Cerecetto, H. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.07.018 · Cited by 49
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation
Papadopoulou, M. V., Bloomer, W. D., Rosenzweig, H. S., O’Shea, I. P., Wilkinson, S. R., Kaiser, M., Chatelain, E., & Ioset, J. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.014 · Cited by 48
Rodríguez, J., Arán, V. J., Boiani, L., Olea‐Azar, C., Lavaggi, M. L., González, M., Cerecetto, H., Maya, J. D., Carrasco‐Pozo, C., & Cosoy, H. S. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.030 · Cited by 48
Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design
Karoli, T., Becker, B., Zuegg, J., Möllmann, U., Ramu, S., Huang, J. X., & Cooper, M. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008882 · Cited by 45
Millet, R., Urig, S., Jacob, J., Amtmann, E., Moulinoux, J.-P., Gromer, S., Becker, K., & Davioud–Charvet, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050256l · Cited by 45
Najib, J. S. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80071-0 · Cited by 44
Kumar, P., Shustov, G. V., Liang, H., Khlebnikov, V., Zheng, W., Yang, X., Cheeseman, C. I., & Wiebe, L. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2017336 · Cited by 44
Papadopoulou, M. V., Bloomer, W. D., Rosenzweig, H. S., Wilkinson, S. R., & Kaiser, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.045 · Cited by 43
A New Synthetic Agent with Potent but Selective Cytotoxic Activity against Cancer
Cholody, W. M., Kosakowska‐Cholody, T., Hollingshead, M. G., Hariprakasha, H. K., & Michejda, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048946x · Cited by 42
Fonseca-Berzal, C. R., Ibáñez‐Escribano, A., Reviriego, F., Cumella, J., Morales, P., Jagerovic, N., Nogal‐Ruiz, J. J., Escario, J. A., da Silva, P. B., Soeiro, M. D. N. C., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.036 · Cited by 40
Tiwari, R., Möllmann, U., Cho, S., Franzblau, S. G., Miller, P. A., & Miller, M. J. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500039g · Cited by 39
Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues
Jiang, H., Xing, J., Wang, C., Zhang, H., Yue, L., Wan, X., Chen, W., Ding, H., Xie, Y., Tao, H., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02369c · Cited by 39
Tercel, M., Lee, H. H., Mehta, S. Y., Youte, J., Bai, S. Y., Liyanage, H. D. S., & Pruijn, F. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00563 · Cited by 37
Self-citationCheng, W., Zhu, S., Ma, X., Qiu, N., Peng, P., Sheng, R., & Hu, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.010 · Cited by 34
Mukkavilli, R., Pinjari, J., Patel, B., Sengottuvelan, S., Mondal, S., Gadekar, A. R., Verma, M., Patel, J., Pothuri, L., Chandrashekar, G., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.09.006 · Cited by 34
Nitrotriazole- and Imidazole-Based Amides and Sulfonamides as Antitubercular Agents
Papadopoulou, M. V., Bloomer, W. D., Rosenzweig, H. S., Arena, A., Arrieta, F., Rebolledo, J. C. J., & Smith, D. K. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03644-14 · Cited by 31
The antitubercular activity of various nitro(triazole/imidazole)-based compounds
Papadopoulou, M. V., Bloomer, W. D., & Rosenzweig, H. S. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.037 · Cited by 30
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
Meng, F., Bhupathi, D., Sun, J. D., Liu, Q., Ahluwalia, D., Wang, Y., Matteucci, M. D., & Hart, C. P. (2015) · BMC Cancer · doi:10.1186/s12885-015-1387-6 · Cited by 28
FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells
Su, J., Guise, C. P., & Wilson, W. R. (2013) · Biochemical Journal · doi:10.1042/bj20121695 · Cited by 27
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers
Bonnet, M., Hong, C. R., Gu, Y., Anderson, R. F., Wilson, W. R., Pruijn, F. B., Wang, J., Hicks, K. O., & Hay, M. P. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.039 · Cited by 26
Zhang, X., Wojtkowiak, J. W., Martinez, G. V., Cornnell, H. H., Hart, C. P., Baker, A. F., & Gillies, R. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155289 · Cited by 25
Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate Mutagenicity
Landge, S. S., Ramachandran, V., Kumar, A., Neres, J., Murugan, K., Sadler, C., Fellows, M. D., Humnabadkar, V., Vachaspati, P. R., Raichurkar, A. V., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201500462 · Cited by 24
Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia
Winn, B. A., Shi, Z., Carlson, G. J., Wang, Y., Nguyen, B. L., Kelly, E. M., Ross, R., Hamel, E., Chaplin, D. J., Trawick, M. L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.11.093 · Cited by 24
McNamara, Y. M., Cloonan, S. M., Knox, A. J. S., Keating, J. J., Butler, S. G., Peters, G. H. J., Meegan, M. J., & Williams, D. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.11.054 · Cited by 23
Lindquist, K. E., Cran, J., Kordic, K., Chua, P. C., Winters, G. C., Tan, J. S., Lozada, J., Kyle, A. H., Evans, J., & Minchinton, A. I. (2013) · Tumor Microenvironment and Therapy · doi:10.2478/tumor-2013-0003 · Cited by 23
de Carvalho, A. S., Salomão, K., de Castro, S. L., Conde, T. R., Zamith, H. P. D. S., Caffarena, E. R., Hall, B. S., Wilkinson, S. R., & Boechat, N. (2014) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-0276140497 · Cited by 23
NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis
Papadopoulou, M. V., Bloomer, W. D., & McNeil, M. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.01.015 · Cited by 21
Tan, S., He, F., Kong, T., Wu, J., & Liu, Z. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.062 · Cited by 21
Papadopoulou, M. V., Bloomer, W. D., Rosenzweig, H. S., & Kaiser, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.060 · Cited by 21
Karwa, A. S., Poreddy, A. R., Asmelash, B., Lin, T., Dorshow, R. B., & Rajagopalan, R. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2001483 · Cited by 20
WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway
Kosakowska‐Cholody, T., Cholody, W. M., Monks, A. P., Woynarowska, B. A., & Michejda, C. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0170 · Cited by 19
Biotransformations Leading to Toxic Metabolites
Macherey, A., & Dansette, P. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00025-0 · Cited by 18
Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase
Zhu, R., Seow, H. A., Baumann, R. P., Ishiguro, K., Penketh, P. G., Shyam, K., & Sartorelli, A. C. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.008 · Cited by 17
Penketh, P. G., Baumann, R. P., Shyam, K., Williamson, H. S., Ishiguro, K., Zhu, R., Eriksson, E. S. E., Eriksson, L. A., & Sartorelli, A. C. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01193.x · Cited by 12
Colón, I. G., González, F. A., Cordero, M., Zayas, B., Vélez, C., Cox, O., Kumar, A., & Alegrı́a, A. E. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800076c · Cited by 7
Nitroimidazole Antibacterial Agents
Anderson, R. J., Groundwater, P. W., Todd, A., & Worsley, A. J. (2012) · Wiley eBooks · doi:10.1002/9781118325421.ch4 · Cited by 6
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Šikorová, E., Štěpánková, Š., Frýbová, E., Konečná, K., Korbielová, J., Švarcová, M., Janďourek, O., Pflégr, V., Bősze, S., & Krátký, M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70188 · Cited by 3
Metadata
- Authors
- Nepali, K., Lee, H.-Y., & Liou, J.-P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-10-08
- Volume
- 62
- Issue
- 6
- Pages
- 2851-2893
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2897075077
- Cited by
- 629
- References
- 87
- FWCI
- 90.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.